Perlen Packaging Group has expanded its position in the pharmaceutical packaging market following the acquisition of LOG Pharma, adding bottles and closures to a portfolio that has traditionally been strongly associated with blister films.
The deal gives Perlen a broader range of primary packaging formats for prescription medicines and over-the-counter products. The company now offers solutions spanning bottles, closures and barrier films, allowing pharmaceutical manufacturers to source packaging technologies for different dosage forms and product requirements from a more integrated portfolio.
The expansion also strengthens Perlen’s capabilities in medical flexible packaging, particularly for pharmaceutical products that require protection from moisture, oxygen and other environmental factors that can affect product stability. By combining its established blister film expertise with LOG Pharma’s experience in bottles and closures, the company is seeking to address protection requirements across multiple packaging formats.
The move comes as pharmaceutical manufacturers increasingly place greater emphasis on packaging performance alongside drug formulation and manufacturing. Primary packaging plays a critical role in maintaining product quality throughout transportation, storage and use, particularly for medicines that are sensitive to humidity or oxygen.
For packaging suppliers, this has created demand for materials and formats that can deliver stronger barrier performance while meeting regulatory, operational and sustainability requirements. Perlen’s acquisition provides the company with an opportunity to broaden its offering as pharmaceutical customers look for packaging partners capable of supporting different product categories.
LOG Pharma Acquisition Broadens Packaging Capabilities
Before the acquisition, Perlen Packaging had built its reputation around pharmaceutical blister packaging, with barrier films designed to protect medicines from external conditions. The addition of LOG Pharma introduces a complementary packaging segment focused on bottles and closures.
The combined portfolio is intended to support pharmaceutical products in different formats while maintaining a common focus on product protection. Bottles can provide practical solutions for tablets, capsules and other oral medicines, while blister films remain an important option where unit-dose protection and barrier performance are required.
The acquisition therefore goes beyond simply adding another product category. It allows Perlen to connect two areas of pharmaceutical packaging expertise and offer customers a wider selection of primary packaging technologies.
LOG Pharma’s bottle and closure capabilities are particularly relevant for products where packaging must control exposure to moisture and oxygen. These requirements can become increasingly important as pharmaceutical formulations become more sensitive to environmental conditions and manufacturers seek to maintain stability throughout a product’s shelf life.
The combination also gives Perlen a stronger platform from which to work with pharmaceutical manufacturers on packaging selection. Instead of focusing on a single format, the company can now provide solutions across different primary packaging requirements.
Paul D’Adamo, North America sales director at Perlen Packaging Group, said the acquisition brings together the company’s experience in blister films with LOG Pharma’s bottling capabilities.
He described the combined business as a more comprehensive primary packaging provider for the global pharmaceutical industry, while emphasizing protection of medicines, patients and pharmaceutical brands.
The broader portfolio could also provide commercial advantages as pharmaceutical companies manage increasingly complex supply chains. Packaging suppliers with capabilities across multiple formats can potentially support customers through product launches, reformulations and changes in dosage forms without requiring a completely new supplier relationship.
Barrier Packaging Becomes Increasingly Important for Pharma
The strategic value of the acquisition is closely linked to the growing importance of barrier properties in pharmaceutical packaging. Exposure to moisture, oxygen, light and other environmental factors can influence the stability and shelf life of medicines, making packaging an essential part of product protection.
Perlen has developed significant experience in high-barrier blister films, while LOG Pharma brings expertise in bottles and closures. Bringing these capabilities together allows the group to address barrier requirements in both flexible and rigid packaging formats.
This is particularly relevant as pharmaceutical companies continue to develop medicines that may require tighter environmental protection. Packaging must not only contain a product but also help preserve its intended quality from manufacturing through distribution and ultimately to the patient.
For pharmaceutical manufacturers, packaging decisions can also influence production efficiency, storage requirements and regulatory compliance. A packaging solution therefore needs to balance protection with manufacturability, usability and supply reliability.
Perlen’s expanded portfolio places the company in a stronger position to participate in these decisions earlier in the product development process. The acquisition could enable the group to offer different combinations of packaging materials and formats depending on a drug’s specific protection requirements.
Sustainability is another consideration shaping the pharmaceutical packaging sector. Companies are under increasing pressure to examine material use, waste and the environmental impact of packaging without compromising the protection required for medicines. Perlen said the combined business will maintain a focus on protecting patients, the environment and the reputation of pharmaceutical customers.
The acquisition also strengthens Perlen’s presence in North America through LOG Pharma’s existing capabilities, while contributing to the group’s wider international packaging offering.
From an industry perspective, the transaction illustrates how pharmaceutical packaging companies are broadening their portfolios beyond individual formats. As drug products become more diverse, suppliers are looking to provide packaging solutions that can accommodate different formulations, delivery methods and protection requirements.
Perlen’s move into bottles and closures gives it a more diversified position across primary pharmaceutical packaging. The company’s existing blister film business and the newly acquired bottle capabilities can now operate as complementary parts of a broader offering.
For pharmaceutical manufacturers, the immediate significance is greater access to packaging options under one supplier. For Perlen, the acquisition creates an opportunity to strengthen its role in the global pharmaceutical packaging value chain while expanding beyond its traditional focus on blister films.
As pharmaceutical packaging requirements continue to evolve, the ability to combine barrier protection, multiple packaging formats and manufacturing expertise is likely to become increasingly important. Perlen’s acquisition of LOG Pharma represents a strategic step in that direction.
Ref: https://www.contractpharma.com/breaking-news/perlen-packaging-expands-into-pharma-bottles-market/
